POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Male Reproductive Cancers Resource Center

Viewpoints

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

The right time for American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) on metastatic castration-resistant prostate cancer.

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.

Feature Articles

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

Male Reproductive Cancers Resources

More Male Reproductive Cancers Resources

Managing Bone Health in Prostate Cancer

This fact sheet answers some common questions about prostate cancer, bone scan, and metastasis.

Prostate Cancer: What to Know About Screening, Diagnosis

This fact sheet reviews current prostate cancer screening tests, guidelines, PSA, and risk factors.

Testicular Cancer Fact Sheet

This fact sheet provides information on symptoms, pain, causes, and treatments for testicular, testicle cancer.

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

ZYKADIA™ (ceritinib)

ZYKADIA™ (ceritinib)

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table ...

PURIXAN® (mercaptopurine [6-MP] oral suspension)

PURIXAN® (mercaptopurine [6-MP] oral suspension)

This slideshow reviews drug information for PURIXAN® (mercaptopurine [6-MP] oral suspension), indicated for acute lymphoblastic leukemia.

Table of Contents

Slide 3: Indication, ...

SYLATRON® (peginterferon alfa-2b)

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: ...

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs